Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H27NO |
Molecular Weight | 309.4452 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CCCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=OGAKLTJNUQRZJU-UHFFFAOYSA-N
InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2
Diphenidol, a nonphenothiazinic antiemetic agent used primarily in patients with Meniere disease and labyrinthopathies to treat vomiting and vertigo, is considered to be a relatively safe drug. Since it was first approved in the United States in 1967, this drug has been widely used in Latin America and Asia and has contributed to sporadic suicidal and accidental poisonings in mainland China and Taiwan. The mechanism by which diphenidol exerts its antiemetic and antivertigo effects is not precisely known. It is thought to diminish vestibular stimulation and depress labyrinthine function and as an antimuscarinic agent. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Diphenidol has no significant sedative, tranquilizing, or antihistaminic action. It has a weak peripheral anticholinergic effect. Diphenidol is used to relieve or prevent nausea, vomiting, and dizziness caused by certain medical problems.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.drugbank.ca/drugs/DB01231 |
6.37 null [pKi] | ||
Target ID: CHEMBL211 Sources: https://www.drugbank.ca/drugs/DB01231 |
5.55 null [pKi] | ||
Target ID: CHEMBL245 Sources: https://www.drugbank.ca/drugs/DB01231 |
5.95 null [pKi] | ||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18395442 |
6.04 null [pKi] | ||
Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18395442 |
5.89 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VONTROL Approved UseINDICATIONS
VERTIGO—‘Vontrol’ is indicated in peripheral (labyrinthine) vertigo and associated nausea and vomiting, as seen in such conditions as: Meniere’s disease, middle- and inner-ear surgery (labyrinthitis).
NAUSEA AND VOMITING—‘Vontrol’ is indicated in the control of nausea and vomiting, as seen in such conditions as: postoperative states, malignant neoplasms and labyrinthine disturbances. Launch Date1967 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
157.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18506741/ |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPHENIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
445.57 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18506741/ |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPHENIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18506741/ |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPHENIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg/kg single, intravenous Highest studied dose Dose: 15 mg/kg Route: intravenous Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: tachyarrhythmias Age Group: adult Sex: unknown Population Size: 18 Sources: |
Disc. AE: Central nervous system disorder NOS... AEs leading to discontinuation/dose reduction: Central nervous system disorder NOS (14 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Central nervous system disorder NOS | 14 patients Disc. AE |
15 mg/kg single, intravenous Highest studied dose Dose: 15 mg/kg Route: intravenous Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: tachyarrhythmias Age Group: adult Sex: unknown Population Size: 18 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats. | 1995 Nov |
|
Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study. | 2005 Sep |
|
Determination of difenidol hydrochloride by capillary electrophoresis with electrochemiluminescence detection. | 2006 Feb 2 |
|
Capillary electrophoresis with end-column electrochemiluminescence for the analysis of chloroquine phosphate and the study on its interaction with human serum albumin. | 2007 Jun 22 |
|
Enzymatic preparation of cefaclor with immobilized penicillin acylase. | 2008 |
|
(2-Methyl-phen-yl)(phen-yl)methanol. | 2010 Jul 31 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cons/diphenidol.html
For oral dosage form (tablets):
Adults: 25 to 50 milligrams (mg) every four hours as needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22683869
In vitro binding assays demonstrated that difenidol at micromolar concentrations bound to the α(1A)-, α(1B)- and α(1D)-adrenoceptor subtypes. Difenidol inhibited the phenylephrine-induced increase in [Ca(2+)](i) in Chinese hamster ovary cells expressing human α(1A)-, α(1B)- or α(1D)-adrenoceptor subtypes with similar IC(50) values in the low micromolar range.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000009034
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
||
|
NDF-RT |
N0000009034
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
||
|
NDF-RT |
N0000178372
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
||
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m4611
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
4638
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
972-02-1
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
NQO8R319LY
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
C65421
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
213-540-9
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
SUB07121MIG
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL936
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
23370
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000083173
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
3055
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
1433
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
313
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
DB01231
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
DTXSID3022950
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
C004858
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
3316
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
DIPHENIDOL
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY | |||
|
7163
Created by
admin on Fri Dec 15 15:14:18 GMT 2023 , Edited by admin on Fri Dec 15 15:14:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)